EXECUTIVE SUMMARY

MEGGA MIX: Food-Derived Oral Antibodies Supporting Gut Health in High-Risk Seniors

MEGGA MIX-CDI Executive Summary
1

Overview

C. difficile infection (CDI) is a major hospital-acquired complication, particularly in seniors receiving antibiotics. MEGGA MIX is a food-derived, orally administered antibody product under clinical development for prevention of CDI in patients aged 65 and older during and after antibiotic therapy.

MEGGA MIX is designed to target C. difficile components locally in the gut without disrupting beneficial microbiota, offering a non-antibiotic approach to risk reduction.

2

The Problem

  • Each year, 8 million USA hospitalized patients aged ≥65 receive antibiotics.
  • Approximately 3% may develop CDI following gut microbiome disruption.
  • CDI increases length of stay, readmission rates, and mortality risk in older patients, and contributes substantially to healthcare costs.
3

The Solution

MEGGA MIX is a daily egg-based antibody powder, typically administered during antibiotic therapy and continued through post-discharge.

Mechanism
Designed to neutralize C. difficile causing components in the gut.
Duration
Standard course 18 days, adjustable with prolonged antibiotic therapy.
Cost per patient
$500 per course (370 g pouch).
Clinical Development Stage
Phase 2 therapeutic trials underway to evaluate safety, tolerability, and biological activity.
4

Economic Potential

Projected impact (assuming efficacy demonstrated in ongoing studies):

Lower CMS penalties for hospital-acquired infections
Reduced readmissions
Shorter hospital stays
Improved quality metrics and public ratings

Example Hospital Projections (illustrative only):

Small community hospital (75 beds)
Annual courses 720
Projected savings ~$180k
Large regional hospital (300 beds)
Annual courses 3,000
Projected savings ~$750k
Disclaimer: These figures are estimates based on modeled outcomes and are dependent on clinical efficacy being demonstrated in trials.
5

Implementation Advantages

Safe and simple: Orally administered, minimal workflow disruption
Scalable: Standardized egg-based production at high volume
Supports CMS priorities: Preventive interventions, improved quality, cost containment
6

Call to Action (FDA-Safe)

MEGGA MIX is currently being evaluated in clinical studies and may be considered for:

✓
Research integration with hospital antibiotic protocols for patients 65+
✓
Pilot programs with government and private payers to evaluate preventive outcomes
Safe
Simple
Scalable
Cost-effective